Business Context and Reporting Period
Scilex Holding Company filed this Form 8-K on June 27, 2023, reporting a new revolving credit facility entered into by its wholly owned subsidiary, Scilex Pharmaceuticals Inc. The Company guaranteed the subsidiary’s obligations.
Key Financial Terms and Metrics
- Facility size: Revolving loans of up to $30.0 million, subject to a borrowing base limitation equal to the lesser of the facility cap and 85% of eligible receivables’ net collectible value, less lender reserves or adjustments.
- Interest rate: The Wall Street Journal Prime Rate plus 1.50%, payable monthly in arrears beginning July 1, 2023.
- Maturity: All outstanding amounts are due July 1, 2026, unless the facility is terminated earlier.
- Collateral: The facility is secured primarily by accounts receivable, related deposit accounts, and other defined collateral. A blocked-account arrangement permits the lender to sweep collection proceeds toward amounts outstanding.
- Liquidity covenant: The Borrower must maintain cash in controlled deposit accounts plus revolving-facility availability of at least $1.0 million at all times.
- Use of proceeds: Transaction fees, working capital, and other permitted corporate purposes.
- The filing does not provide revenue, profit, cash flow, margin, balance-sheet, debt-balance, or facility-utilization amounts as of the reporting date.
Material Changes Versus the Prior Comparable Period
The filing reports the creation of a new secured revolving borrowing arrangement and a related parent guaranty. It does not provide comparative-period financial statements or quantify changes in operating results, liquidity, or leverage.
Guidance, Outlook, Risks, and Unusual Items
- The Facility Cap may be increased in $250,000 increments with lender consent when outstanding borrowings equal or exceed 95% of the then-current cap.
- A 0.50% early termination fee applies if the Borrower voluntarily prepays and terminates the facility in full before the first anniversary of closing.
- Covenants restrict, subject to exceptions, additional indebtedness and liens, mergers and acquisitions, asset dispositions, dividends or other distributions, related-party transactions, and investments.
- An event of default includes a Borrower change of control and the Company’s failure to issue at least $75.0 million of debt or equity by September 30, 2023.
- Customary defaults, including certain insolvency events, could result in termination of commitments and acceleration of all amounts due. Insolvency-related defaults trigger automatic termination and acceleration.
- The Company’s guaranty exposes it to the subsidiary’s payment and performance obligations under the Credit Agreement.
Important Facts for Investors to Verify
- Actual borrowings, availability, interest expense, and unused capacity under the facility.
- Compliance with the $1.0 million minimum liquidity covenant and other restrictive covenants.
- Whether the required $75.0 million debt or equity issuance was completed by September 30, 2023.
- The composition and collectibility of eligible receivables supporting borrowing capacity.
- Any subsequent defaults, amendments, waivers, lender sweeps, or changes to the parent guaranty.
- Complete terms and omitted provisions in Exhibits 10.1 and 10.2, including information redacted as confidential.